Aflac Inc. Reports Third‑Quarter 2026 Results: A Scrutiny of Earnings Decline, Reserve Dynamics, and Shareholder Returns

Aflac Inc. filed a Form 8‑K with the Securities and Exchange Commission on November 4, 2026, announcing its third‑quarter results for the fiscal year. While the company reiterated its commitment to a balanced growth strategy, the numbers reveal a sharp contraction in core profitability and a complex interplay of reserve remeasurements, investment performance, and claims costs. Below is an investigative analysis that dissects the figures, questions official explanations, and explores the implications for policyholders, investors, and the broader insurance landscape.

1. Net Earnings Decline: Surface vs. Substance

  • Reported Net Earnings: Declined by 38 % compared with the same quarter a year earlier, translating to earnings per share (EPS) that dropped from $3.30 to $1.97.
  • Adjusted Earnings: Fell by 22 %, a less steep decline that reflects gains from reserve remeasurement and a modest decline in investment income.

Why the Adjustment Matters

Aflac’s adjusted earnings exclude what the company calls “non‑recurring items” and reserve remeasurements. While this metric can smooth volatility, it also masks underlying profitability concerns:

  • Reserve Remeasurement Gains: A significant portion of the adjusted earnings boost stems from a $120 million increase in reserves for long‑term policies, a figure that has not been historically consistent. This raises questions about the sustainability of such gains and whether they merely shift liability estimates rather than improve cash flow.
  • Investment Income: The reported decline in investment income by $30 million is partially attributed to a downturn in the bond market and a shift to higher‑yield but riskier assets. The company’s narrative frames this as a temporary blip, yet the trend toward riskier portfolios could expose policyholder payouts to future market volatility.

2. Revenue Contraction: Premiums vs. Investment Losses

  • Total Revenue: Fell from $4.73 billion to $3.32 billion, a loss of $1.41 billion.
  • Premiums: Reduced by $700 million due to lower growth in the U.S. market and a slight decline in the Japan division.
  • Investment Losses: Accounted for a $600 million shortfall, driven by a drop in fixed‑income yields and a cautious stance on equity exposure.

Investigative Lens

The revenue decline invites scrutiny over Aflac’s pricing strategy and claims management:

  • Premium Pricing: Aflac’s premium growth in the U.S. was only 5 % year‑over‑year, markedly lower than the industry average of 9 %. This suggests a possible erosion of competitive advantage or a shift toward a less profitable customer base.
  • Claims Costs: The increase in benefits and claims expenses by $150 million coincides with a broader trend of rising medical costs. However, Aflac has not disclosed the proportion of these costs attributable to the new “accelerated payment” program, which could represent a hidden liability.

3. Operating Expenses and Claims: Where the Cost is Burdening Policyholders

  • Operating Expenses: Rose by $20 million, reflecting higher marketing spend aimed at penetrating new demographics.
  • Benefits & Claims: Increased by $140 million, driven by higher payouts for cancer and heart disease claims.

Questioning the Narrative

While Aflac claims these costs are “in line with industry benchmarks,” external actuarial analyses indicate that the company’s claims ratio has climbed from 68 % to 73 % over the past two quarters—an uptick that could pressure future profitability if not managed.

4. Shareholder Equity and Value Return

  • Shareholder Equity: Gained $50 million, a modest increase that may signal cautious capital deployment.
  • Return to Shareholders: A combination of share repurchases and dividends, with a fourth‑quarter dividend of $0.61 per share (up from $0.60).

Conflict of Interest Considerations

The continued dividend increases, despite declining earnings, raise concerns:

  • Dividend Sustainability: Historical cash flow data shows that dividends are paid from both operating cash flow and, increasingly, from retained earnings. A flurry of share repurchases during earnings declines can artificially inflate earnings per share, creating a deceptive picture of performance.
  • Capital Allocation: The balance between dividend payouts and reinvestment in high‑yield, high‑risk assets may signal a prioritization of short‑term shareholder value over long‑term policyholder solvency.

5. Geographic Performance: U.S. vs. Japan

  • U.S. Division: Reported higher premiums and adjusted earnings, driven by a 4 % increase in earned premiums and a $10 million improvement in reserve gains.
  • Japan Division: Experienced a slight decline in earned premiums and adjusted earnings due to reinsurance transactions and adverse yen depreciation.

Investigative Angle

Aflac’s narrative of a “balanced growth strategy” glosses over the Japan division’s exposure to currency risk and its reliance on reinsurance to cushion losses. The company’s disclosures lack detail on the terms of these reinsurance contracts, obscuring whether policyholder benefits could be diluted if reinsurance coverage lapses or becomes more expensive.

6. Reserve Gains and Corporate Operations

  • Reserve Gains: $120 million contributed positively to adjusted earnings, stemming largely from corporate and other operations.
  • Corporate Expenses: Increased by $30 million, attributed to “technology upgrades” and “global expansion efforts.”

Scrutinizing Reserve Practices

The magnitude and timing of reserve gains suggest an aggressive strategy to shift liability estimates upward, potentially to smooth earnings in volatile markets. Regulators typically require conservative reserve assumptions; deviations could attract scrutiny from state insurance commissioners and the SEC.

7. Human Impact: Policyholders and Employees

  • Policyholders: The rise in benefits and claims expenses translates to higher payout commitments. With premiums contracting, there may be pressure on the company to raise future premiums, impacting affordability for lower‑income policyholders.
  • Employees: Increased marketing spend may create new hiring opportunities, but the company’s focus on capital deployment could limit long‑term investment in employee development.

8. Conclusion: Accountability Amidst Ambiguity

Aflac Inc.’s third‑quarter results paint a complex picture. While the company frames adjusted earnings and dividend growth as positive signals, the underlying financial health—characterized by shrinking revenue, rising claims costs, and aggressive reserve remeasurement—raises legitimate concerns. Stakeholders, particularly policyholders and investors, should demand greater transparency on:

  • The sustainability of reserve gains and their impact on future solvency.
  • The risk profile of investment portfolios and how they align with policyholder obligations.
  • The long‑term viability of dividend payouts amidst declining net earnings.

Only through rigorous scrutiny of financial data and questioning of official narratives can the true health of Aflac be discerned and its accountability ensured.